These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 15869730)

  • 1. Treatment of metastatic malignant melanoma.
    Atallah E; Flaherty L
    Curr Treat Options Oncol; 2005 May; 6(3):185-93. PubMed ID: 15869730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic melanoma.
    Sun W; Schuchter LM
    Curr Treat Options Oncol; 2001 Jun; 2(3):193-202. PubMed ID: 12057119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Serrone L; Zeuli M; Sega FM; Cognetti F
    J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
    Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current therapy for malignant melanoma.
    Legha SS
    Semin Oncol; 1989 Feb; 16(1 Suppl 1):34-44. PubMed ID: 2465575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
    Huncharek M; Caubet JF; McGarry R
    Melanoma Res; 2001 Feb; 11(1):75-81. PubMed ID: 11254118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of metastatic melanoma with chemotherapy and biologics.
    Atkins MB
    Curr Opin Oncol; 1997 Mar; 9(2):205-13. PubMed ID: 9161801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of malignant melanoma at the stage of distant metastasis].
    Garbe C; Eigentler TK
    Hautarzt; 2004 Feb; 55(2):195-213. PubMed ID: 15043023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
    Garbe C
    Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic chemotherapy in the treatment of malignant melanoma.
    Lens MB; Eisen TG
    Expert Opin Pharmacother; 2003 Dec; 4(12):2205-11. PubMed ID: 14640919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The treatment of brain metastases from malignant melanoma.
    Douglas JG; Margolin K
    Semin Oncol; 2002 Oct; 29(5):518-24. PubMed ID: 12407517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic melanoma: a regional review and future directions.
    Khan KH; Goody RB; Hameed H; Jalil A; Coyle VM; McAleer JJ
    Tumori; 2012; 98(5):575-80. PubMed ID: 23235751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of metastatic cutaneous melanoma.
    Buzaid AC
    Oncology (Williston Park); 2004 Oct; 18(11):1443-50; discussion 1457-9. PubMed ID: 15609471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
    Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P
    Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent interleukin-2 in the treatment of metastatic melanoma.
    Petrella T; Quirt I; Verma S; Haynes AE; Charette M; Bak K;
    Curr Oncol; 2007 Feb; 14(1):21-6. PubMed ID: 17576460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.
    Keilholz U; Scheibenbogen C; Brossart P; Möhler T; Tilgen W; Hunstein W
    Recent Results Cancer Res; 1995; 139():383-90. PubMed ID: 7597305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.